July 2 Preclinical Quick Takes: Semma plans 2020 clinical trials of stem cell-derived islet products and more

Semma to bring stem cell-derived islet therapies for diabetes to clinic in 2020
Semma Therapeutics Inc. (Cambridge, Mass.) plans to start Phase I testing in early 2020 of its stem cell-derived islets combined with immunosuppression in "brittle"

Read the full 369 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers